摘要
目的：总结经尿道膀胱肿瘤电切（TUR-BT）术后辅以沙培林（注射用A群链球菌）联合丝裂霉素（MMC）膀胱内灌注治疗高危膀胱癌的疗效。方法：回顾性研究2009年1月~2012年8月我院收治的符合高危非肌层浸润性膀胱癌患64例,观察组：TUR-BT术后行沙培林联合MMC膀胱内灌注化疗32例,对照组;MMC单药灌注32例。结果：观察组患者,平均年龄63.7岁,治疗随访时间为6~54个月,中位时间27.3个月。治疗随访期间有3例患者出现膀胱内肿瘤复发（9.3%）,1例患者疾病进展,发展为肌层浸润性膀胱癌,于术后7个月死亡（3.1%）。与对照组患者相比,疾病复发率及进展率均明显改善。结论：高危非肌层浸润膀胱癌临床复发率、进展率高,TUR-BT术后沙培林联合MMC膀胱内灌注通过局部化疗及免疫治疗联合,可有效控制疾病的复发和进展,降低患者接受膀胱部分切除或膀胱全切手术的机率,值得推广。
Objective： To discuss our experiences of irrigation of bladder with a select group of patients with high-risk non-muscle invasive bladder cancer after TUR-BT. Methods： We performed a retrospective cohort study in patients diagnosed with high-risk non-muscle invasive bladder cancer,64 cases, from 2009.01 to 2012.08. Observational group, 32 patients were underwent transurethral resection immediately. Then they were offered irrigation of bladder with Streptococcus A Group Injection and Mitomycin（MMC） by turns. Control group were offered irrigation of bladder only with MCC after the operation. Results： The data from obsevational patients were gathered and analyzed. The average patients age was 63.7 years. The follow-up time was 6~54 months. The median time of patients remained in observation was 27.3 months. After 54 months, 9.37 % of the patients had recurrence and 3.12 % had progressed in stage,who experienced progression to muscle-invasive stage, and died 7 months later after the operation. The comparison between the rates of recurrence and progression with control group showed statistically significant difference. Conclusion： Patients with high-risk nonmuscle-invasive bladder tumors are common and recurrent easily, and can be efficiently treated by irrigation of bladder with Streptococcus A Group Injection and Mitomycin（MMC） by turns after TUR-BT, thus reducing the amount of surgical intervention that they might undergo throughout their lives.
出处
《现代生物医学进展》
CAS
2013年第30期5913-5915,共3页
Progress in Modern Biomedicine
关键词
高危非肌层浸润性膀胱癌
膀胱灌注
免疫治疗
High-risk non-muscle invasive bladder cancer
Irrigation of bladder
Immunotherapy
作者简介
曹志强（1977一），男，副教授，主要研究方向：下尿路疾病诊治，泌尿系肿瘤，干细胞基础研究，E-mail：cao_zhi_qiang@yahoo．com．cn
通讯作者：刘龙，电话：024—28851201，E-mail：13309888392@189．cn
